IL22RA1 (interleukin 22 receptor, alpha 1)

2010-02-01   Pascal Gelebart , Raymond Lai 

Department of Laboratory Medicine, Pathology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada




Atlas Image
Representation of the IL22RA1 gene organization. IL22RA1 gene and RNA.


The gene spans a region of 23.3 kb including seven exons.


One only transcript form containing 7 exons has been described. The last exon is partially untranslated. The transcript length is 1725 nucleotides, encoding a protein of 594 amino acid residues.




Atlas Image
IL22RA1 protein organization and localization. IL22RA1 protein domains.


IL22RA1 is composed of 574 amino acid residues, and the predicted molecular weight of the immature protein is 63 kDa. IL22RA1 protein is composed of six putative domains, including the signal peptide (residue 1 to 15), the extracellular domain (residue 16 to 228), the transmembrane domain (residue 229 to 249), the cytoplasmic domain (residue 250 to 574), and two fibronectin type-III domains (residue 18-115 and 141-221).
Atlas Image
Crystal structure of IL22RA1 with IL22 at 1.9 A resolution. Adapted from PDB (access number: 3DLQ).


IL22RA1 expression is relatively restricted, being found at the highest level in the pancreas, small intestine, colon, kidney, and liver. Importantly, IL22RA1 is not detectable in normal immune cells, including monocytes, B-cells, T-cells, natural killer cells, macrophages and dendritic cells, cell types that are normally found in the bone marrow, peripheral blood, thymus and spleen.
Atlas Image
FACS analysis of IL22RA1 expression in peripheral mononuclear cells from healthy donor.


IL22RA1 is localized at the plasma membrane.
Atlas Image
Localization of IL22RA1 by immunufluorescence confocal microscopy in ALK+ALCL cells.


IL22RA1 is one of the subunits of the IL20, IL22 and IL24 receptor complex. Cytokine binding to IL22RA1 results in its aggregation, which activates the associated JAK via its autophosphorylation. This in turn leads to the phosphorylation and activation of STAT proteins. Subsequently, phosphorylated STAT proteins dimerize and translocate to the nucleus to modulate the transcription of various target genes.
Atlas Image
IL22RA1 signaling.



Site-directed mutagenesis experiments have revealed critical amino acid residues involved in its binding to IL22. Specifically, mutation of residue 58 from K to A reduces the binding of IL22. Mutation of the residue 60 from Y to A or R results in a complete loss of response to IL22.
Natural IL22RA1 variants have been reported, including those carrying mutations at the residue 130 (S to P), 205 (V to I), 209 (A to S), 222 (L to P), 407 (M to V) and 518 (R to G).

Implicated in

Anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL), or ALK+ALCL, is a specific type of non-Hodgkin lymphoma characterized by the T/null-cell immunophenotype, consistent expression of CD30 and reciprocal chromosomal translocations involving the ALK gene. In most cases, the chromosomal translocation is that of the t(2;5)(p23;q35), which leads to the juxtaposition of the nucleophosmin (NPM) gene at 5q35 with the ALK gene at 2p23. Mounting evidence suggests that the resulted oncogenic fusion protein, NPM-ALK, plays crucial roles in the pathogenesis of these tumors.
Patients with ALK+ALCL are typically treated with combination chemotherapy containing doxorubicin. ALK+ALCL represents one of the most common pediatric lymphoid malignancies. The prognosis of pediatric ALK+ALCL patients is significant better than that of adult patients.
t(2;5)(p23;q35) in most ALK+ALCL patients; other translocation variants have been described.
Hybrid gene
Atlas Image
Representation of the NPM-ALK oncoprotein organization and sequence.
Fusion protein
Atlas Image
Structure of the oncogenic fusion protein NPM-ALK.
Aberrant expression of IL22RA1 in ALK+ALCL lymphoma cells allows these cells to be responsive to IL-22 stimulation, which further stimulate STAT3 signaling and the growth of these cells. Blocking the IL-22 signaling pathway using a neutralizing antibody has been shown to significantly decrease the growth of ALK+ALCL cells in-vitro. The aberrant expression of IL22RA1 in ALK+ALCL is dependent on the expression of NPM-ALK, since siRNA to downregulate NPM-ALK dramatically shut down IL22RA1 expression.


Pubmed IDLast YearTitleAuthors
175193892007Pathobiology of ALK+ anaplastic large-cell lymphoma.Amin HM et al
185093512008Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma.Bard JD et al
186758092008Crystal structure of the IL-22/IL-22R1 complex and its implications for the IL-22 signaling mechanism.Bleicher L et al
196329852009New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain.Dumoutier L et al
193934222009Polymorphisms in the interleukin-22 receptor alpha-1 gene are associated with severe chronic rhinosinusitis.Endam LM et al
110350292001Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes.Kotenko SV et al
124070262002IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells.Lécart S et al
117060202002Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2.Wang M et al
180245072008Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor Oliveira Neto M et al

Other Information

Locus ID:

NCBI: 58985
MIM: 605457
HGNC: 13700
Ensembl: ENSG00000142677


dbSNP: 58985
ClinVar: 58985
TCGA: ENSG00000142677


Gene IDTranscript IDUniprot

Expression (GTEx)



PathwaySourceExternal ID
Cytokine-cytokine receptor interactionKEGGko04060
Jak-STAT signaling pathwayKEGGko04630
Cytokine-cytokine receptor interactionKEGGhsa04060
Jak-STAT signaling pathwayKEGGhsa04630
Immune SystemREACTOMER-HSA-168256
Cytokine Signaling in Immune systemREACTOMER-HSA-1280215
Signaling by InterleukinsREACTOMER-HSA-449147
Interleukin-19, 20, 22, 24REACTOMER-HSA-8854691


Pubmed IDYearTitleCitations
192400612009Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling.75
248561432014The role of the IL-22/IL-22R1 axis in cancer.48
228989222012Th17-associated cytokines promote human airway smooth muscle cell proliferation.44
185992992008Structure of IL-22 bound to its high-affinity IL-22R1 chain.42
186758092008Crystal structure of the IL-22/IL-22R1 complex and its implications for the IL-22 signaling mechanism.34
197313622009IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression.30
202374962010New genetic associations detected in a host response study to hepatitis B vaccine.27
209719502011A novel role for IL-22R1 as a driver of inflammation.22
295722242018IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer.21
196329852009New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain.20


Pascal Gelebart ; Raymond Lai

IL22RA1 (interleukin 22 receptor, alpha 1)

Atlas Genet Cytogenet Oncol Haematol. 2010-02-01

Online version: